Select Bibliography

Filter by any of these (after searching):

Hubbard, Joleen M.

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 2 items

Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group trial N0745 (Alliance)

Hubbard, Joleen M. , Mahoney, Michelle R. , Loui, William S. ... - - Target Oncol - 2017

Manuscript - Primary - Primary - GI - NCCTG-N0745

Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance)

Xie, Hao , Lafky, Jacqueline M. , Morlan, Bruce W. ... - - Ther Adv Med Oncol - 2020

Manuscript - Primary - Primary - GI - NCCTG-N054C